Señales en vivo de PROG | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 may 2022 @ 00:00):

Stats
Volumen de hoy	2.78M
Volumen promedio	6.37M
Capitalización de mercado	8.18M
EPS	$-0.0640 ( 2022-05-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.257
ATR14	$0.131 (14.81%)

Insider Trading

Date	Person	Action	Amount	type
2022-04-15	Desparbes Eric	Buy	231 693	Common Stock
2022-04-15	Neumann Clarke	Buy	184 843	Common Stock

INSIDER POWER
0.00
Last 2 transactions
Buy: 416 536 \| Sell: 0

Volumen Correlación

Largo: 0.62 (weak)

Corto: 0.84 (strong)

Signal:(38.248) Same movement expected

Progenity, Inc. Correlación

10 Correlaciones Más Positivas
ALR	0.96
VRAY	0.953
SNAX	0.951
TBLT	0.951
AGRI	0.949
IRBT	0.948
IMBI	0.948
TENX	0.947
ENNV	0.946
HILS	0.944

10 Correlaciones Más Negativas
TIOAU	-0.951
BRIVU	-0.95
NVCN	-0.95
ADTH	-0.947
MSDA	-0.947
AGNCP	-0.939
VLAT	-0.937
STAY	-0.937
TIOA	-0.936
NTNX	-0.933

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Progenity, Inc. Correlación - Moneda/Commodity

-0.69
( moderate negative )

-0.82
( strong negative )

0.00
( neutral )

-0.54
( weak negative )

-0.33
( neutral )

0.54
( weak )

Progenity, Inc. Finanzas

Annual	2023
Ingresos:	$4 000.00
Beneficio Bruto:	$-551 000 (-13 775.00 %)
EPS:	$-7.87

FY	2023
Ingresos:	$4 000.00
Beneficio Bruto:	$-551 000 (-13 775.00 %)
EPS:	$-7.87

FY	2022
Ingresos:	$305 000
Beneficio Bruto:	$-602 000 (-197.38 %)
EPS:	$-6.40

FY	2021
Ingresos:	$1.25M
Beneficio Bruto:	$1.25M (100.00 %)
EPS:	$-9.18

Financial Reports:

No articles found.

Progenity, Inc.

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.